The participants of the 2017 BioCanRx-Cancer Stakeholder Alliance Learning Institute wish to share their Community Dissemination Report with the oncology patient and researcher community, BioCanRx, the Cancer Stakeholder Alliance, and the general public.
In this report, you will find the key research take-away messages and the Learning Institute’s group reflections on the topics listed below that were presented at the Summit for Cancer Immunotherapy in June 2017:
- The Microbiome (Plenary Session 1)
- Clinical, Social & Economic Impact (Plenary Session 2)
- Novel preclinical models & in vitro screening platforms (Plenary Session 3)
- Antibodies & Antibody-like Molecules (Plenary Session 4)
- Innate Immunity (Plenary Session 5)
- Oncolytic Viruses & Viral Vaccines (Plenary Session 6)
- Adoptive Cell Therapy: Beyond Melanoma (Plenary Session 7)
- Biomarkers & Immune Profiling (Plenary Session 8)
- Panel Discussion: Companion Diagnostics Discussion
For more information about the Summit for Cancer Immunotherapy, please visit here.
For more information about The Learning Institute, please visit here.
“I believe we have created something special here. Something worth building on. Something that will change the culture of cancer research and improve the scientific enterprise.”
– Patrick Sullivan, Cancer Stakeholder Alliance Working Group Chair
“Based on the overwhelmingly positive feedback, the Learning Institute has become a permanent component of our annual Summit for Cancer Immunotherapy. We are looking forward to hosting the second event at the next Summit in October 2018.”
– Dr. Stephanie Michaud, President and CEO of BioCanRx, and Dr. John Bell, Scientific Director of BioCanRx
